Eterna Therapeutics and Factor Bioscience Announce Exclusive License and Collaboration Agreement to Accelerate Cell Therapy Development for Oncology, Autoimmune, and Rare Diseases
Eterna Therapeutics and Factor Bioscience Announce Exclusive License and Collaboration Agreement to Accelerate Cell Therapy Development for Oncology, Autoimmune, and Rare Diseases
CAMBRIDGE, Mass., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) ("Eterna" or the "Company") and Factor Bioscience Limited ("Factor") today announced an exclusive license and collaboration agreement aimed at accelerating the development of advanced cell therapy candidates for oncology, rare diseases, and autoimmune disorders. Under the terms of the agreement, Eterna has secured a worldwide, exclusive, non-transferable, royalty-bearing license, with the right to grant sublicenses, to develop and market certain induced pluripotent stem cell (iPSC)-based cell therapy products (in particular iPSC derived mesenchymal stem cells (iMSC) that are engineered to express certain cytokines) utilizing Factor's cell reprogramming and gene-editing technologies, patents, and know-how. The agreement positions both companies with the potential to accelerate the development of advanced cell therapies in the oncology, rare disease, and autoimmune fields.
馬薩諸塞州劍橋市,2024年10月17日(環球新聞社) - Eterna Therapeutics Inc.(納斯達克:ERNA)("Eterna"或"公司")與Factor Bioscience Limited("Factor")今日宣佈達成專屬許可和合作協議,旨在加快腫瘤、罕見病和自身免疫性疾病的先進細胞療法候選品的開發。根據協議條款,Eterna已獲得全球獨家、不可轉讓、有版稅的許可,有權授予子許可,開發和營銷特定誘導多能幹細胞(iPSC)爲基礎的細胞療法產品(特別是經過基因編輯和表達某些細胞因子的iPSC來源間充質幹細胞(iMSC)),利用Factor的細胞重編程和基因編輯技術、專利和專業知識。該協議使兩家公司有望加速在腫瘤、罕見病和自身免疫領域先進細胞療法的發展。
"We are excited to collaborate with Factor to unlock the full potential of these transformative cell therapies," said Sanjeev Luther, Eterna's President & CEO. "Our focus at Eterna has always been on developing transformative treatments for patients with difficult-to-treat diseases, and we believe this collaboration agreement increases our potential to rapidly advance therapies that target solid tumors, rare diseases, and autoimmune disorders."
"我們很高興與Factor合作,釋放這些變革性細胞療法的全部潛力," Eterna的總裁兼首席執行官Sanjeev Luther說。"Eterna一直專注於爲難治療疾病患者開發變革性治療方法,我們相信這一合作協議增加了我們迅速推進治療固定腫瘤、罕見病和自身免疫性疾病的潛力。"
Eterna and Factor will collaborate on data generation that seeks to demonstrate efficacy of the licensed drug candidates for development towards IND by Eterna directly or with third-party sublicensees. As part of the agreement, Factor Bioscience is entitled to milestone payments per product candidate, as well as post-commercialization royalties.
Eterna和Factor將就產生數據而展開合作,旨在證明獲得許可藥物候選品的有效性,以便Eterna直接或與第三方子許可人進行IND發展。根據協議的規定,Factor Bioscience有權獲得每個產品候選品的里程碑付款,以及商業化後的版稅。
"We are thrilled to support Eterna's pipeline of advanced cell therapy product candidates," said Matt Angel, Ph.D., CEO of Factor Bioscience. "Eterna's team has deep translational and development expertise, making them the ideal partner to develop these products. Together, we are taking an important step toward making these therapies available to patients in need."
"我們很高興支持Eterna的先進細胞療法產品候選品計劃," Factor Bioscience的首席執行官Matt Angel博士表示。"Eterna團隊具有深厚的轉化和開發專業知識,使其成爲開發這些產品的理想合作伙伴。我們共同邁出了使這些療法面向需要的患者的重要一步。"
About Eterna Therapeutics Inc.
Eterna Therapeutics is a publicly traded, preclinical-stage company focused on using cutting-edge tools to deliver highly innovative, effective, and safe off-the-shelf cell therapies for the treatment of advanced solid tumors, with an initial emphasis on triple-negative breast cancer (TNBC) and platinum-resistant, TP53-mutant ovarian cancer. The company is currently focused on advancing its lead product ERNA-101, an induced allogenic mesenchymal stem cell (iMSC) product, designed to selectively deliver the pro-inflammatory cytokines IL-7 and IL-15 to the tumor microenvironment (TME) in order to drive significant anti-tumor immunity. ERNA-101 is built on the company's in-licensed core technology, which utilizes a best-in-class approach to engineer allogenic iPSCs to express genes of interest and to efficiently differentiate these cells into iMSCs. For more information, please visit
關於愛文思控股治療公司
愛文思控股是一家上市的、處於臨床前階段的公司,專注於使用尖端工具爲治療愛文思控股的先進實體瘤而開發高度創新、有效且安全的現貨細胞療法,最初重點放在三陰性乳腺癌(TNBC)和對鉑抗性、TP53突變卵巢癌的治療上。該公司目前專注於推進其主導產品ERNA-101,這是一種誘導的異基因間充質幹細胞(iMSC)產品,旨在有選擇性地向腫瘤微環境(TME)遞送促炎細胞因子IL-7和IL-15,以促進顯著的抗腫瘤免疫反應。 ERNA-101建立在公司許可的核心技術基礎之上,利用一流方法來設計異基因誘導多能幹細胞(iPSCs)以表達感興趣基因,並有效地將這些細胞分化爲iMSCs。欲了解更多信息,請訪問
About Factor Bioscience
Founded in 2011, Factor Bioscience is the leading cell engineering platform technology company working to harness the potential of cell engineering to treat disease and improve health. Factor Bioscience is privately held and headquartered in Cambridge, MA. For more information, visit
關於愛普思生物公司
Factor Bioscience成立於2011年,是一家領先的細胞工程平台技術公司,致力於利用細胞工程的潛力治療疾病並改善健康。Factor Bioscience是一傢俬人持有的公司,總部設在馬薩諸塞州劍橋。欲了解更多信息,請訪問
Forward-Looking Statements
前瞻性聲明
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements, in some cases, can be identified by terms such as "believe," "may," "will," "estimate," "continue," "anticipate," "design," "intend," "expect," "could," "plan," "potential," "predict," "seek," "should," "would," "contemplate," "project," "target," "objective," or the negative version of these words and similar expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Eterna's actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by the forward-looking statements in this press release, including, without limitation, risks and uncertainties related to: Eterna's ability to raise capital when and as needed to advance its product candidate, execute its business strategy and continue as a going concern; the performance ability of Eterna's in-licensed core technology; the outcome of collaborations with third-parties; and the evolution of Eterna's business model into a preclinical-stage company focused on the treatment of advanced solid tumors, rare diseases. Forward-looking statements are based upon the company's current expectations and involve assumptions that may never materialize or may prove to be incorrect. All forward-looking statements are expressly qualified in their entirety by these cautionary statements. For a detailed description of the company's risks and uncertainties, you are encouraged to review its documents filed with the SEC including its recent filings on Form 8-K, Form 10-K and Form 10-Q. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Eterna does not undertake any obligation to update the forward-looking statements contained herein to reflect events that occur or circumstances that exist after the date hereof, except as required by applicable law.
本新聞稿包含《1933年證券法》第27A條修正案和《1934年證券交易法》第21E條修正案的前瞻性聲明,旨在受1995年《私人證券訴訟改革法》的安全港規定保護。前瞻性聲明有時可通過"相信","可能","將","估計","持續","預期","設計","打算","期望","可能","計劃","潛在","預測","尋求","應當","將","沉思","項目","目標"等詞語或類似表達來識別。前瞻性聲明涉及已知和未知風險、不確定性和可能導致艾特娜(Eterna)實際結果、績效或成就與本新聞稿中前瞻性聲明所表達或暗示的未來結果、績效或成就實質上不同的其他因素,包括但不限於與:艾特娜能否在需要時籌集資金以推進其產品候選進展,執行其業務策略並繼續作爲一個持續經營的公司;艾特娜被許可的核心技術的性能能力;與第三方合作的結果;以及艾特娜業務模式向專注於治療先進固體腫瘤、罕見疾病的臨床前階段公司的演變有關的風險和不確定性。前瞻性聲明基於該公司目前的期望,並涉及可能永遠不會實現的假設,或可能被證明不正確的假設。所有前瞻性聲明在其整體上都受到這些警告性聲明的明確限制。有關該公司風險和不確定性的詳細描述,建議您查看其提交給證券交易委員會的文件,包括其最近在8-k表格、10-k表格和10-Q表格上的提交。請注意,不要過分依賴前瞻性聲明,因爲它們僅適用於發佈日期。艾特娜不會更新此處包含的前瞻性聲明,以反映此後發生的事件或存在的情況,除非適用法律要求。
Investor Relations Contact:
投資者關係聯繫人:
investors@eternatx.com
investors@eternatx.com
譯文內容由第三人軟體翻譯。